Answers are grounded in this paper and cite their sources.
Background Mesenchymal stromal cells (MSCs) possess potent immunomodulatory properties, but the mechanisms through which they shape innate-adaptive immune interactions remain poorly understood. Given the functional plasticity of neutrophils, we investigated whether MSCs induce an immunoregulatory neutrophil phenotype capable of suppressing autologous T-cell responses and examined the mechanisms involved. Methods Ex vivo models were used to investigate MSC-neutrophil interactions and the capacity of MSC-conditioned neutrophils to modulate activated autologous T-cells. Direct and transwell co-culture systems were employed to evaluate the roles of cell contact and soluble mediators. Results Neutrophils acquired MSC-derived material through an oxygen-dependent phagocytosis process, which induced a regulatory phenotype referred to as “programmed neutrophils”. Compared with untreated controls, these cells exhibited enhanced survival and effectively suppressed autologous T-cell responses by limiting early activation events, as evidenced by reduced CD25 expression prior to HLA-DR upregulation. T-cell suppression required direct neutrophil-T-cell interaction, whereas neutrophil programming occurred independently of physical contact with MSCs. MSC-conditioned medium alone was sufficient to influence neutrophil phenotype, implicating MSC-derived extracellular vesicles (EVs) as mediators of the reprogramming signal. Furthermore, both viable and apoptotic MSCs generated comparable effects, supporting a central role for MSC-driven neutrophil reprogramming in the development of immunosuppressive neutrophils. Conclusions Our study uncovers a novel MSC-neutrophil immunoregulatory pathway in which MSC-programmed neutrophils acquire suppressive activity and regulate adaptive immune responses. This mechanism enables MSCs to indirectly control T-cell activation and highlights neutrophil reprogramming as a central component of MSC immunomodulation, with potential applications in the development of potency assays and biomarkers for MSC-based therapies.
No takes yet. Share an insight, caveat, or question.
Tomaipitinca et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: